Listar GI-FENM - Artigos por autor "Castellano, Daniel"
Mostrando ítems 1-3 de 3
-
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
Castellano, Daniel; Antón-Aparicio, Luis M.; Esteban, Emilio; Sánchez-Hernández, Alfredo; Germá, José Ramón; Batista, Norberto; Maroto, Pablo; Pérez-Valderrama, Begoña; Luque, Raquel; Méndez-Vidal, María José (Taylor & Francis, 2014-07-07)[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel. METHODS: This multi-centre ... -
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
Capdevila, Jaume; Sevilla, Isabel; Alonso, Vicente; Antón-Aparicio, Luis M.; Jiménez Fonseca, Paula; Grande, Enrique; Reina, Juan José; Manzano, José Luis; Alonso Lájara, Juan Domingo; Barriuso, Jorge; Castellano, Daniel; Medina, Javier; López, Carlos; Segura, Ángel; Carrera, Sergio; Crespo, Guillermo; Fuster, José; Munarriz, Javier; García Alfonso, Pilar (BioMed Central, 2015-07-04)[Abstract] Background. Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine ... -
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Puente, Javier; Lainez, Nuria; Dueñas, Marta; Méndez-Vidal, María José; Esteban, Emilio; Castellano, Daniel; Martínez-Fernández, Mónica; Basterretxea, Laura; Juan-Fita, María José; Antón-Aparicio, Luis M.; León, Luis; Lambea, Julio; Pérez-Valderrama, Begoña; Vázquez, Sergio; Suárez, Cristina; García del Muro, Xavier; Gallardo, Enrique; Maroto, José Pablo; Samaniego, M. Luz; Suárez-Paniagua, Beatriz; Sanz, Julián; Paramio, Jesús M. (Impact Journals, 2017-03-23)[Abstract] Background: Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further ...